Neumora is a clinical-stage biopharmaceutical company developing brain-penetrant small-molecule therapies for neuropsychiatric, neurodegenerative, and metabolic disorders by integrating novel drug discovery with proprietary precision neuroscience capabilities to identify and monitor targeted patient populations. The company's pipeline includes lead program navacaprant, a kappa opioid receptor antagonist for major depressive disorder, alongside candidates targeting Alzheimer's disease agitation, schizophrenia, obesity, Parkinson's disease, and ALS, developed through exclusive licenses from institutions including Amgen and Vanderbilt University. Neumora has no approved products or revenue and operates a research and development operation outsourcing manufacturing, planning to generate returns through milestone payments and royalties on future product commercialization if clinical candidates succeed and reach the market.